EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease Control

Frank Siebenhaar, Senan Sofi, Sophia Neisinger, Cem Akin, Polina Pyatilova, Eva Grekowitz, Antje Haendel, Tomasz Hawro, Lea Kiefer, Markus Magerl, Martin Metz, Marcus Maurer und 1 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2025-03 · 13 (3) · 647-657.e3

DOI: 10.1016/j.jaip.2024.11.021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2025-03. Verfasst von Frank Siebenhaar und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin…. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Mastocytosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charité - Universitätsmedizin Berlin.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Mastocytosis is characterized by expanding neoplastic mast cells in organs such as the skin, bone marrow, and gastrointestinal tract. The release of mast cell mediators triggers cutaneous, gastrointestinal, and other symptoms. Currently, no validated mastocytosis-specific patient-reported outcome measure (PROM) exists to assess disease control. OBJECTIVE: Here, we developed a disease-specific instrument, the Mastocytosis Control Test (MCT), for evaluating and monitoring disease control in patients with nonadvanced disease. METHODS: Six potential MCT items were generated using a combined approach consisting of a literature review, patient interviews, and expert input. Item selection and reduction were performed by impact analysis and interitem correlation, followed by expert reviews and cognitive debriefings. In a validation study, the resulting MCT was tested for validity and reliability by assessing internal consistency, test-retest reliability, convergent validity, known-groups validity, and receiver operating characteristics (ROC) analysis. RESULTS: Ten patients participated in the item generation phase and 101 in the item reduction and validation phase. The final MCT consisted of 5 items. Our methods showed a valid total score, high internal consistency, and test-retest reliability. Convergent and known-groups validity demonstrated a strong correlation with related anchors. The ROC curve analysis suggested a cutoff value of ≥13 points to identify patients with good disease control. CONCLUSIONS: The MCT is a disease-specific, valid, and reliable PROM for adult patients with nonadvanced disease. It may measure and monitor disease control in routine daily practice and clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresMastocytosisHumansMaleFemaleMiddle AgedAdultAgedReproducibility of ResultsSurveys and Questionnaires

Stichwörter der Autor:innen

Control testImpact analysisMastocytosisQuality of lifeSymptoms

Autor:innen und Institutionen

  • Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Insititute for Translational Medicine and Pharma…
  • Division of Allergy and Clinical Immunology, University of Michigan, Ann Arbor, Mich.
  • Patient Advocacy Group, Mastozytose e.V., Toenisvorst, Germany.
  • Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Department of Dermatology, Allergology and Venereology, Uni…

Förderung

  • Charité - Universitätsmedizin Berlin

Zitieren

APA

Siebenhaar, F., Sofi, S., Neisinger, S., Akin, C., Pyatilova, P., Grekowitz, E., Haendel, A., Hawro, T., Kiefer, L., Magerl, M., Metz, M., Maurer, M., & Weller, K. (2025). The Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease Control. The Journal of Allergy and Clinical Immunology: In Practice, 13(3), 647-657.e3. https://doi.org/10.1016/j.jaip.2024.11.021

Vancouver

Siebenhaar F, Sofi S, Neisinger S, Akin C, Pyatilova P, Grekowitz E, et al. The Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease Control. The Journal of Allergy and Clinical Immunology: In Practice. 2025;13(3):647-657.e3. doi:10.1016/j.jaip.2024.11.021

BibTeX
@article{Siebenhaar2025,
  author = {Siebenhaar, Frank and Sofi, Senan and Neisinger, Sophia and Akin, Cem and Pyatilova, Polina and Grekowitz, Eva and Haendel, Antje and Hawro, Tomasz and Kiefer, Lea and Magerl, Markus and Metz, Martin and Maurer, Marcus and Weller, Karsten},
  title = {The Mastocytosis Control Test: A Patient-Reported Outcome Measure Assessing Disease Control},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {647--657.e3},
  doi = {10.1016/j.jaip.2024.11.021}
}
Kostenlos starten →